Clinical trials: Dyspnea
Dyspnea, Chest Pain
Contactless Ultrasound Data Acquisition in Emergency Departments to Discriminate the Origin of Dyspnea and Chest Pain
PAnDA-One is a prospective, multicenter, interventional study (10 centers, France) aimed at developing and validating a diagnostic support algorithm based on the ADx-One medical device, which non-invasively acquires thoracic…
- Trial name
- PAnDA-One (NCT07653204)
- Testing
- All patients from both groups will be imaged with airborne ultrasound device
- Where
- France
- Volunteers
- 2,500 people
- Sponsor
- Austral Diagnostics
Asthma
Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
This study aimed to determine the efficacy and safety of QAW039 150 mg and QAW039 450 mg, compared with placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016)…
- Trial name
- NCT02555683
- Testing
- QAW039
- Where
- 234 sites in United States, Argentina and 25 more
- Volunteers
- 894 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
A Real-World Assessment of a COPD Disease Management Support Service (Me & My COPD)
A real world study to determine the effectiveness of a patient support service to aid COPD patients in their self management.
- Trial name
- Me&MyCOPD (NCT02300090)
- Testing
- Test Group, Control Group
- Where
- 23 sites in United Kingdom
- Volunteers
- 161 people
- Sponsor
- AstraZeneca
Asthma, Pneumonia
PECO Air Purification in Hospital Rooms to Improve Health Outcomes for Pediatric Respiratory Distress
This study will investigate the efficacy of a novel air purification technology, Photo Electrochemical Oxidation (PECO), has on pediatric patients hospitalized for respiratory distress.
- Conditions
- Asthma, Pneumonia, Respiratory Distress Syndrome
- Trial name
- NCT03647397
- Testing
- Photo Electrochemical Oxidation (PECO) for Air Purification
- Where
- United States
- Volunteers
- 274 people
- Sponsor
- Molekule
Asthma
Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma
The purpose of this study is to determine the efficacy of indacaterol 55µg once daily (and 27.5 µg twice) in QVA149 compared to 75 µg indacaterol monotherapy.
- Trial name
- QAB149 (NCT01959412)
- Testing
- Indacaterol 27.5 mcg, Indacaterol 37.5, Indacaterol 55 mcg
- Where
- 12 sites in United States
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
COPD Exacerbation, CHF
Evaluation of the Multidimensional Dyspnea Profile (MDP)
Aim of this multicenter prospective cohort study is the evaluation of the multidimensional qualities of dyspnea in a number of diseases using the Multidimensional Dyspnea Profile (Banzett et al, ERJ 2015).
- Conditions
- COPD Exacerbation, CHF, OSA, COPD
- Trial name
- NCT04090671
- Testing
- Multidimensional Dyspnea Profile
- Where
- 4 sites in Germany
- Volunteers
- 400 people
- Sponsor
- Institut für Pneumologie Hagen Ambrock eV
Asthma
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
This study is a randomized, double-blind, placebo-controlled, three-period cross-over study in approximately 54 subjects with asthma.
- Trial name
- NCT03257995
- Testing
- Indacaterol maleate, Indacaterol acetate
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath
The study does not involve testing of a drug (no treatment intervention). The study will will use spirometry (breathing tests) in subjects of 40 years of age and older with a history of cigarette smoking with chronic bronchitis…
- Trial name
- NCT00442468
- Testing
- Non-interventional study.
- Where
- 47 sites in United States
- Volunteers
- 1,283 people
- Sponsor
- GlaxoSmithKline
Asthma, Bronchospasm
Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics
This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine Inhalation Aerosol USP, an HFA-MDI (E004), using a stable isotope deuterium-labeled epinephrine (epinephrine-d3) to differentiate the…
- Conditions
- Asthma, Bronchospasm, Wheezing, Shortness of Breath
- Trial name
- NCT01188577
- Testing
- Epinephrine Inhalation Aerosol, HFA, Epinephrine Inhalation Aerosol
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Pulmonary Disease, Chronic Obstructive
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
The objective of this study is to demonstrate that, when added to tiotropium (TIO), fluticasone propionate/salmeterol combination (FSC) DISKUS 250/50 significantly increases exercise endurance time (EET) in the endurance shuttle…
- Trial name
- ESWT (NCT01124422)
- Testing
- fluticasone propionate/salmeterol inhalation powder DISKUS 250/50, tiotropium bromide inhalation powder HandiHaler
- Where
- 27 sites in United States, Canada
- Volunteers
- 255 people
- Sponsor
- GlaxoSmithKline
Chronic Nasal Congestion, Lung Infection
Biomarker for Cystic Fibrosis
International, multicenter, observational, longitudinal study to identify biomarker/s for Cystic fibrosis and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s
- Conditions
- Chronic Nasal Congestion, Lung Infection, Breathlessness, Clubbing Toes
- Trial name
- BioCyFi (NCT02710383)
- Where
- 5 sites in Albania, Georgia and 3 more
- Volunteers
- 54 people
- Sponsor
- CENTOGENE GmbH Rostock
Breathlessness, COPD
Sentinel - Triaging Acute Breathlessness Using Multi-Modal Biomarkers
The Sentinel-001 study aims to identify a combination of biomarkers suitable for triage of breathlessness.
- Conditions
- Breathlessness, COPD, Asthma, Asthma Chronic
- Trial name
- NCT05304494
- Testing
- Biomarker tests for participant profiling
- Sponsor
- Sanome
Shortness of Breath
A Validation Study to Evaluate the Performance of Caption Health Lung Guidance and Interpretation
The purpose of this study is to assess the efficacy of Caption LungAI.
- Trial name
- NCT05992324
- Testing
- Caption LungAI
- Where
- 4 sites in United States
- Volunteers
- 220 people
- Sponsor
- Caption Health, Inc.
Dyspnea, Hypertension
Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF
The purpose of this study is to evaluate dyspnea improvement and other parameters of efficacy and safety in acute heart failure (AHF) patients receiving an intravenous (IV) infusion of clevidipine in comparison to standard of…
- Conditions
- Dyspnea, Hypertension, Acute Heart Failure
- Trial name
- PRONTO II (NCT04592380)
- Testing
- Stage 1: Clevidipine (double-blinded), Stage 2: Clevidipine (open-label), Stage 2: Standard of Care (open-label)
- Where
- 9 sites in United States
- Sponsor
- The Medicines Company
Atrial Fibrillation Paroxysmal, Atrial Fibrillation, Persistent
Assert-IQ Implantable Cardiac Monitor (ICM) Post Market Study
This is a prospective, non-randomized, multi-center, real-world post-market study to collect and evaluate data regarding the performance of the enhanced atrial fibrillation detection algorithm of the Assert-IQTM Implantable…
- Conditions
- Atrial Fibrillation Paroxysmal, Atrial Fibrillation, Persistent, Cardiac Arrhythmia, Ablation
- Trial name
- Assert-IQ (NCT06172699)
- Testing
- Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device
- Where
- 11 sites in United States
- Volunteers
- 151 people
- Sponsor
- Abbott Medical Devices
Heart Failure
Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)
The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction hospitalized for acute heart…
- Trial name
- NCT01300013
- Testing
- Omecamtiv mecarbil
- Where
- 150 sites in United States, Australia and 17 more
- Volunteers
- 614 people
- Sponsor
- Cytokinetics
Asthma
Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma
The purpose of this study is to evaluate the efficacy, safety and tolerability of JNJ-39758979 compared with placebo in patients with uncontrolled asthma despite current treatment with inhaled corticosteroids and/or long-acting…
- Trial name
- NCT01493882
- Testing
- JNJ-39758979 30 mg/d, JNJ-39758979 100 mg/d, JNJ-39758979 300 mg/d
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acute Respiratory Distress Syndrome, Coronavirus
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical…
- Conditions
- Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure
- Trial name
- VANGARD (NCT04433546)
- Testing
- Pemziviptadil (PB1046), Low Dose (10 mg) Control
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Asthma (Diagnosis)
Longitudinal Phenotyping and Endotyping Study in Adult Patients With Mild, Moderate, or Severe Asthma
Background and study aims: The purpose of this research registry is to understand how asthma varies from person to person and monitor changes that may occur over time.
- Trial name
- MAPLE-UK (NCT07189806)
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Hvivo
Chronic Obstructive Pulmonary Disease (COPD)
Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)
This study compared the safety and efficacy of indacaterol 150 µg taken once daily (o.d.) versus salmeterol 50 µg taken twice daily (b.i.d) in patients 40 years old or older with chronic obstructive pulmonary disease.
- Trial name
- INSIST (NCT00821093)
- Testing
- Indacaterol 150 µg, Salmeterol 50 µg
- Where
- 144 sites in United States, Czechia and 6 more
- Volunteers
- 1,123 people
- Sponsor
- Novartis Pharmaceuticals